Over the past half-century, therapeutic cancer vaccines (TCVs) have been investigated as a potential immunotherapeutic approach to treat cancer by stimulating CD8 + cytotoxic T cells to generate tumor-specific responses. The gene discussed is CD8A; the disease is cancer.